AstraZeneca

Milestones as listed on astrazeneca.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Leadership as listed on astrazeneca.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Products and services as listed on astrazeneca.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

Sites as listed on astrazeneca.com, checked 26 Sep 2026. Details can change; the linked page is the authoritative source.

What public registers list for AstraZeneca (group figures): clinical trials it sponsors, FDA device clearances, Irish licences, recent approvals and supply shortages. Rebuilt daily, last on 10 Oct 2026.

Clinical trials 463 in our ClinicalTrials.gov registers · 33 in the EU register

Showing 10 of 463, trials with Irish sites first. The full lists are on the sponsor pages below.

All trials by sponsor name 2 registry names

Drugs in these trials 195 compounds

EU trials register (CTIS) 33 authorised or ongoing · 1 in Ireland

• The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab2024-518858-17-00 · Phase II · Ongoing · site in Ireland
• Phase III, Open-label Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety, Efficacy, and Immunogenicity of Benralizumab in Children with Eosinophilic Disease (CLIPS)2023-508533-14-00 · Phase III · Ongoing
• A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)2025-523285-25-00 · Phase III · Ongoing
• A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)2024-519786-22-01 · Phase I/II · Authorised
• A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)2023-510098-33-01 · Phase III · Authorised
• A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS)2025-523599-21-00 · Phase II · Authorised
• A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)2025-523994-41-00 · Phase III · Ongoing
• A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).2025-525030-57-00 · Phase III · Ongoing

Recent approvals

• EtcamahEMA · camizestrant · 20 Jul 2026
• EtcamahFDA · Camizestrant · 4 Sep 2026 · New Drug (NDA)
• TruqapFDA · Capivasertib · 16 Nov 2023 · New Drug (NDA)

Medicine shortages 1 in the FDA list

• Pramlintide Acetate InjectionUS (FDA) · resolved · updated 27 Oct 2025

A company is listed here when it is named on the shortage record; a shortage can have several manufacturers. See the US and German shortage trackers.

NICE technology appraisals 47 of its medicines · 47 current

• Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphomaNICE TA1184 · Recommended · 19 Aug 2026
• Acalabrutinib with venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemiaNICE TA1185 · Optimised · 19 Aug 2026
• Durvalumab with chemotherapy for neoadjuvant and adjuvant treatment then alone for adjuvant treatment of resectable gastric or gastro-oesophageal junction adenocarcinomaNICE TA1160 · Recommended · 3 Jun 2026
• Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyNICE TA1156 · Recommended · 21 May 2026
• Sodium zirconium cyclosilicate for treating hyperkalaemiaNICE TA1148 · Optimised · 29 Apr 2026
• Durvalumab with gemcitabine and cisplatin for neoadjuvant treatment then alone for adjuvant treatment of muscle-invasive bladder cancerNICE TA1138 · Recommended · 2 Mar 2026
• Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyNICE TA1099 · Recommended · 1 Oct 2025
• Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitisNICE TA1096 · Optimised · 3 Sep 2025

Appraisals of medicines sold under a brand this company holds in EMA or FDA records, from our NICE appraisals register. NICE decisions apply to the NHS in England. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Group (AstraZeneca): founded 1913, headquarters Cambridge Biomedical Campus, website astrazeneca.com. Wikidata Q731938 · Wikipedia. From Wikidata (CC0), matched by the group's SEC filer number.

How this is matched: register records are linked to this page by the organisation name they carry, here AstraZeneca; MedImmune LLC; AstraZeneca AB; AstraZeneca AB ; ASTRAZENECA; ASTRAZENECA AB and 1 more. Spot a wrong match? Tell us.

From the annual reports AstraZeneca PLC files with the US Securities and Exchange Commission (20-F, IFRS), in USD as reported. Latest financial year: to Dec 2025.

Each year is taken from the most recent annual report that includes it, so earlier years reflect any later restatement. Source: SEC EDGAR (XBRL financial data). Compare companies on the pharma company financials register.

Companies registered in Ireland 4 active in the CRO register

From the Companies Registration Office (CRO Open Data, CC BY 4.0). A company is listed when GLEIF's legal entity register links it to AstraZeneca PLC as its ultimate parent, or when we checked its name and registered address by hand. Branches of foreign companies appear as "External company". Spot a missing or wrong entry? Tell us.